Neurocrine Biosciences ... also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics ...

Takeda Pharmaceutical Company Limited engages ... and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune ...

Professor of Psychiatry and Molecular Medicine, Department of Psychiatry; Hofstra North Shore Long Island School of Medicine, Hempstead, New York; Medical Director, Recognition and Prevention ...

The company has a long list of other collaborators, including AstraZeneca, Neurocrine Biosciences, Biohaven Pharma, GSK, Roche/Genentech, Takeda, Sanofi, and AbbVie.

Sosei Heptares, meanwhile, is partnering with Neurocrine Biosciences on another GPCR-targeting drug, muscarinic M4 agonist NBI-1117568, which has reached the phase 2 testing stage as a ...

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $185.00. The company’s shares closed yesterday at $105.76.

Neurocrine (NBIX) Biosciences announced publication of a post-hoc analysis from two 48-week studies, the KINECT 3 extension and KINECT 4, demonstrating the long-term safety profile and efficacy of ...

The Irish arm of pharma firm, Takeda last year took a €37.2 million hit to profits after mothballing fresh manufacturing capacity at its Grange Castle site in south county Dublin. New accounts ...

(RTTNews) - Neurocrine Biosciences Inc. (NBIX) announced publication of a post-hoc analysis from two 48-week studies, the KINECT 3 extension and KINECT 4, demonstrating the long-term safety ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...